HENDERSON, Nev. / Sep 03, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present at three upcoming investor conferences in September.
Conference Details:
Event: H.C. Wainwright 26th Annual Global Investment Conference
Details: Presenting on Wednesday, September 11, 2024, at 11:30 a.m. ET and hosting investor meetings in New York, NY.
Event: Stifel Immunology and Inflammation Virtual Summit
Details: Presenting on Tuesday, September 17, 2024, at 12:00 p.m. ET and hosting virtual investor meetings.
Event: Cantor Global Healthcare Conference
Details: Presenting on Tuesday, September 17, 2024, at 2:30 p.m. ET and hosting investor meetings in New York, NY.
Links for live webcasts and replays, if available, will be posted on the News & Events page in the Investors & Media section of the Zura Bio website. Presentations will be archived on the website for at least 30 days following the event.
ABOUT ZURA BIO
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.
| Last Trade: | US$3.72 |
| Daily Change: | -0.12 -3.12 |
| Daily Volume: | 450,918 |
| Market Cap: | US$241.870M |
November 13, 2025 May 20, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
